In March of 2022 NASCSA conducted a survey of it’s state members requesting their input on a recent petition submitted Public Citizen
to the FDA and DEA to place gabapentin and gabapentin enacarbil on schedule V of the Controlled Substances Act. Attached please find the
results of the survey that showed overwhelming support for rescheduling the drug to Schedule V and a letter to FDA sharing the survey results.
NASCSA Gabapentin Survey, March 2022